CDK4 and breast carcinoma: Given the survival benefits for advanced ER+ breast cancer observed with all of the CDK4/6 inhibitors developed thus far, their use in adjuvant therapy for early stage, high-risk ER+ breast cancer was studied in several subsequent clinical trials, with somewhat conflicting results.